Pfizer reached four collaborations in two days involving AI pharmaceuticals, in vivo gene editing, etc.

In the past two days, Pfizer announced four important cooperations in succession, introducing a number of advanced technologies to supplement the product pipeline

1.

Under the agreement, Beam will receive a $300 million down payment and is eligible to receive up to $1.

Beam will select 3 undisclosed target candidates for all research activities, which are not included in Beam's existing programs

As part of the collaboration, the efficacy of the developed base editing program will be assessed by delivery to target organs using Beam's proprietary in vivo delivery technology

Beam's proprietary base editing technology is designed to enable a new class of precision genetic medicines that target individual bases in the genome without causing DNA double-strand breaks

In 2012, a research team led by Intellia co-founder Jennifer Doudna won the 2020 Nobel Prize in Chemistry for developing the CRISPR/Cas9 genome editing tool

Results of the first in vivo CRISPR gene editing clinical trial announced, with positive interim data from a Phase I clinical study of NTLA-2001, an in vivo CRISPR-Cas9 genome editing therapy jointly developed by Intellia and Regeneron, in the treatment of transthyretin amyloidosis (ATTR).

2.

Acuitas' clinically proven LNP technology has been used in Pfizer-BioNTech's COVID-19 vaccine COMIRNATY, which has been approved for marketing or emergency use authorization in many countries or regions around the world

3.

Under the agreement, Pfizer paid Dren Bio an upfront payment of $25 million, and the company is also eligible to receive development, regulatory and commercialization milestone payments totaling more than $1 billion

Certain myeloid cells, such as tumor-associated macrophages (TAMs), are part of the tumor microenvironment and are often immunosuppressed, thus being associated with poorer clinical outcomes

Dren Bio's bispecific platform has a powerful multi-pronged mechanism of action, including (i) direct coupling of myeloid and cancer cells, (ii) stimulation of myeloid cells to release key cytokines known to these cells Factors can alter TAMs and reset the immunosuppressive TME (tumor microenvironment)
.
(iii) phagocytosis and killing of tumor cells, (iv) the appearance of tumor neoantigens activates effector T cell and memory T cell responses
.

The fastest-growing dual-antibody elranatamab in Pfizer's pipeline targets CD3/BCMA and is currently in Phase III clinical stage for the treatment of multiple myeloma
.

4.
Expand cooperation with PostEra to develop new drugs based on AI

On January 11, PostEra announced that it has expanded its existing strategic cooperation with Pfizer to establish an artificial intelligence laboratory (AI Lab) to jointly advance the discovery and development of multiple targeted drugs in oncology and COVID-19 antiviral therapy
.

Under the agreement, PostEra will receive an upfront payment of $13 million and is eligible to receive additional milestone payments totaling $248 million, if all milestones are met, in addition to tiered royalties on approved products resulting from any collaboration
.

Based on Pfizer data and PostEra's pioneering innovations in generative chemistry and synthesis-aware design, the AI ​​Lab will leverage novel machine learning techniques for medicinal chemistry research
.

On the same day, PostEra announced the completion of a $24 million Series A financing
.
The new funding will allow PostEra to further expand its collaborative drug discovery programs, launch in-house drug discovery programs, and further develop its artificial intelligence medicinal chemistry platform
.